BACKGROUND: Everolimus-eluting stents (EES) have proven to be safe and effective in randomized clinical trials. This study evaluated the early and late clinical follow-up of patients treated with EES in the daily practice. METHODS: Retrospective study in patients with ischemic coronary disease treated with ESS alone. Patients with "de novo" lesions, in native vessels, were included. Patients were evaluated in the long-term follow-up for the occurrence of death, acute myocardial infarction (AMI) or the need of target-vessel revascularization (TVR). RESULTS: Mean age was 62.1 ± 11.9 years, 75% were male, there was a high percentage of diabetics (49.2%) and 51.6% had stable angina. Multi-vessel disease was observed in 54.8% and moderate to severe left ventricular dysfunction in 11.3%. There was a prevalence of complex B2/C lesions (79%), and the procedure was monitored by intravascular ultrasound in 57.3% of the cases. At least one off-label indication was observed in nearly 60% of the patients. At 1-month follow-up AMI was observed in 2.4%, TVR in 1.6% and stent thrombosis in 1.6% of the patients. Complete long-term data were obtained in 92% of the overall cohort, with a mean follow-up of 16 months. TVR was observed in only 0.9% of the patients and there was no additional AMIs. There were no deaths in this population. CONCLUSIONS: The results of this study suggest that EES implantation in a non-selected population is safe, with a low rate of long-term adverse events.
Angioplasty; Drug-eluting stents; Coronary disease
